{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Alexander JL"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)","Wellcome Trust","Crohn's and Colitis UK"],"pagination":["342-352"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8813209"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(4)"],"pubmed_abstract":["<h4>Background</h4>The effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought to determine whether COVID-19 vaccine-induced antibody responses were altered in patients with IBD on commonly used immunosuppressive drugs.<h4>Methods</h4>In this multicentre, prospective, case-control study (VIP), we recruited adults with IBD treated with one of six different immunosuppressive treatment regimens (thiopurines, infliximab, a thiopurine plus infliximab, ustekinumab, vedolizumab, or tofacitinib) and healthy control participants from nine centres in the UK. Eligible participants were aged 18 years or older and had received two doses of COVID-19 vaccines (either ChAdOx1 nCoV-19 [Oxford-AstraZeneca], "],"journal":["The lancet. Gastroenterology & hepatology"],"pubmed_title":["COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study."],"pmcid":["PMC8813209"],"funding_grant_id":["MR/S034919/1","MR/M00533X/1","220725/Z/20/Z","CL-2019-21-502","M14-5"],"pubmed_authors":["Ramanathan A","Stark H","Saifuddin A","Shah P","Kok K","Ahmad T","Boyton RJ","Sanchez J","Mendoza V","Gros Alcalde B","Sebastian S","Haq S","Romanczuk L","Hart AL","Alexander JL","Williams HRT","Kent AJ","Domingo J","Chukwurah I","Patel M","Cooke G","Covil K","Watkins D","Balarajah S","Patel KV","Goodhand JR","Ibraheim H","Bewshea C","Barnes A","Constable L","Pollock K","Anandabaskaran S","Hicks LC","Shamtally D","Cipriano B","Lee I","VIP study investigators","Teare JP","Liu Z","Parkes M","Derikx L","Kennedy NA","Gardner-Thorpe H","Lees CW","Irving PM","Wilken-Smith S","Powell N","King R","Bee L","Estember C","Stone S","Knight B","Linger R","Castro Seoane R","Fiorentino F","Baden M","D'Mello A","Ruocco G","Altmann DM","Jones GR","Kirkwood J","Parkinson M","Nice R"],"additional_accession":[]},"is_claimable":false,"name":"COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.","description":"<h4>Background</h4>The effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought to determine whether COVID-19 vaccine-induced antibody responses were altered in patients with IBD on commonly used immunosuppressive drugs.<h4>Methods</h4>In this multicentre, prospective, case-control study (VIP), we recruited adults with IBD treated with one of six different immunosuppressive treatment regimens (thiopurines, infliximab, a thiopurine plus infliximab, ustekinumab, vedolizumab, or tofacitinib) and healthy control participants from nine centres in the UK. Eligible participants were aged 18 years or older and had received two doses of COVID-19 vaccines (either ChAdOx1 nCoV-19 [Oxford-AstraZeneca], ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-22T06:00:19.964Z","creation":"2025-02-19T01:34:28.103Z"},"accession":"S-EPMC8813209","cross_references":{"pubmed":["35123676"],"doi":["10.1016/S2468-1253(22)00005-X"]}}